Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy

Stock Information for Capricor Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.